TearClear has filed an investigational new drug application for its glaucoma drop candidate.
If the application is approved, the company plans to initiate a clinical trial to evaluate TC-002 latanoprost ophthalmic solution 0.005%. The solution will be preservative free “to prevent long-term deleterious effects on the eye,” according to a press release.
“We are confident that improving the health of the ocular surface matters,” TearClear CEO Stuart Raetzman said in the release. “Responding to that unmet need has propelled us to this important milestone and it is